In a Pseudomonas aeruginosa multidrug‑resistant isolate that is resistant to carbapenems and most agents but remains susceptible only to fosfomycin, amikacin, and gentamicin, should treatment be an aminoglycoside‑based regimen (amikacin or gentamicin, with or without fosfomycin) or one of Zerbaxa (ceftazidime‑avibactam), Zavicefta (cefiderocol), or colistin (colistimethate sodium)?

Treatment Recommendation for MDR Pseudomonas aeruginosa

For this carbapenem-resistant, multidrug-resistant P. aeruginosa isolate susceptible only to fosfomycin, amikacin, and gentamicin, you should use combination therapy with an aminoglycoside (amikacin preferred over gentamicin) plus fosfomycin for severe infections, or aminoglycoside monotherapy for non-severe infections. Zerbaxa (ceftolozane-tazobactam), Zavicefta (ceftazidime-avibactam), and cefiderocol should be reserved only if they test susceptible in vitro, which is unlikely given your resistance pattern. Colistin should be avoided unless absolutely no other options exist.

Rationale Based on Guidelines and Evidence

Why Aminoglycoside-Based Therapy is Preferred

The 2022 ESCMID guidelines explicitly address your exact scenario 1. For severe carbapenem-resistant P. aeruginosa (CRPA) infections susceptible only to polymyxins, aminoglycosides, or fosfomycin, they conditionally recommend treatment with two in vitro active drugs 1. For non-severe infections, monotherapy with an active agent is acceptable 1.

Amikacin should be prioritized over gentamicin because:

• Broader spectrum against resistant P. aeruginosa
• Better tissue penetration
• More favorable resistance profile
• FDA-approved specifically for P. aeruginosa infections 2

Combination vs. Monotherapy Decision Algorithm

Severe infection indicators (use combination therapy):

• Septic shock or hemodynamic instability
• Bloodstream infection/bacteremia
• Hospital-acquired/ventilator-associated pneumonia
• High bacterial burden infections
• Immunocompromised patients

Non-severe infections (monotherapy acceptable):

• Complicated urinary tract infections without sepsis 1, 3
• Localized soft tissue infections
• Stable patients without organ dysfunction

Why NOT the Newer Agents in Your Case

Zerbaxa (ceftolozane-tazobactam):

• Your isolate is already carbapenem-resistant and MDR to "a lot of drugs"
• Zerbaxa is NOT active against metallo-β-lactamase producers 4
• Cross-resistance with other cephalosporins is common 4
• Only use if susceptibility testing confirms activity 1

Zavicefta/Ceftazidime-avibactam:

• Not active against metallo-β-lactamases 5
• Your resistance pattern suggests likely resistance
• Should be reserved for less resistant isolates per stewardship 1

Cefiderocol:

• While active against many MDR P. aeruginosa including MBL-producers 6, 7
• Should be reserved for failures of other agents 6
• Not first-line when aminoglycosides are active 1
• Requires MIC-guided dosing and therapeutic drug monitoring 6

Colistin:

• High nephrotoxicity risk 3
• Should be avoided when aminoglycosides are available 3
• Reserved for pan-resistant organisms only 1

Practical Implementation

Dosing Strategy

Amikacin (preferred):

• 25-30 mg/kg IV once daily for severe infections
• 15 mg/kg IV once daily for urinary tract infections
• Therapeutic drug monitoring (TDM) is strongly recommended 8
• Target peak 55-60 mcg/mL, trough <5 mcg/mL

Fosfomycin (for combination):

• 6-8 grams IV every 8 hours
• Continuous infusion may optimize exposure
• Monitor for hypokalemia 8

Gentamicin (alternative):

• 5-7 mg/kg IV once daily
• TDM mandatory 8
• Higher nephrotoxicity than amikacin

Critical Monitoring

• Renal function daily - aminoglycosides have narrow therapeutic index 8
• Therapeutic drug monitoring whenever possible 8
• Electrolytes (especially potassium with fosfomycin) 8
• Clinical response at 48-72 hours - if failing, consider cefiderocol with susceptibility testing

Common Pitfalls to Avoid

1. Don't use aminoglycoside monotherapy for severe infections - combination with fosfomycin improves outcomes 1

2. Don't assume newer agents work without testing - your MDR pattern suggests likely resistance to Zerbaxa/Zavicefta 5

3. Don't skip TDM - aminoglycosides require monitoring to balance efficacy and nephrotoxicity 8

4. Don't use colistin first-line - significantly more nephrotoxic than aminoglycosides with similar efficacy 3

5. Don't forget source control - drainage, catheter removal, debridement are essential regardless of antibiotic choice

If Treatment Fails

1. Confirm susceptibility testing accuracy
2. Consider cefiderocol if available and susceptible 6, 7
3. Evaluate for metallo-β-lactamase - if present, aztreonam-based combinations may work 1
4. Reassess source control
5. Consider infectious disease consultation